Aligos Therapeutics (ALGS) Stock Statistics & Valuation Metrics

Aligos Therapeutics has a market cap or net worth of $39.85M. The enterprise value is $14.23M.

Aligos Therapeutics has 5,387,807 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aligos Therapeutics’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -123.88%.

The current PE Ratio of Aligos Therapeutics is ―. Aligos Therapeutics’s PEG ratio is 0.04.

In the last 12 months, Aligos Therapeutics had revenue of 2.19M and earned -24.19M in profits. Earnings per share was -2.45.

In the last 12 months, operating cash flow was -84.72M and capital expenditures -463.00K, giving a free cash flow of -85.19M billion.

Aligos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Aligos Therapeutics upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Aligos Therapeutics as a current ratio of 3.90, with Debt / Equity ratio of 13.69%

In the past 12 months, Aligos Therapeutics has paid 314.00K in taxes.

Aligos Therapeutics EV to EBITDA ratio is -0.91, with an EV/FCF ratio of -0.95.

Aligos Therapeutics has $54.91M in cash and marketable securities with $4.35M in debt, giving a net cash position of $50.56M billion.

Gross margin is 89.03%, with operating margin of -4024.93%, and net profit margin of -1106.72%.

The average price target for Aligos Therapeutics is $73.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy